The Amazing and Deadly Glioma Race  by Ramaswamy, Vijay & Taylor, Michael D.
Cancer Cell
Previewsdata by Dahan et al. (2015), with no evi-
dence for toxicity toward normal somatic
tissues, clinical trials with MSB001078C
need to proceed with care, because PD-
L1 is expressed at considerable levels in
several normal human tissues, including
lung.
In conclusion, new insights into the
function of the IgG isotypes have enabled
modulation of the biological properties
of immune stimulatory Abs, and clinical
trials with more potent formats are immi-
nent. While it is conceivable that fine-
tuning will culminate in mono-specific
drugs with improved therapeutic index,
the importance of tailoring the IgG Fcregions to each target will also add a
layer of complexity to the design of bi-
and dual-specific Abs that are directed
against two different surface molecules.REFERENCES
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In this issue ofCancer Cell, studies fromMazor and colleagues and Kim and colleagues use a combination of
epigenetic and genetic approaches to reveal a complex evolutionary process underlying two of the biggest
challenges facing neuro-oncology, specifically glioblastoma malignant progression and treatment resis-
tance.Gliomas are the most common malignant
brain tumor of adults and are highly treat-
ment resistant. Grade IV gliomas are
called glioblastoma multiforme (GBM)
and are currently classified as primary
GBM or secondary GBM, the latter of
which are presumed to arise from a
lower grade tumor. Secondary GBMs
frequently harbor mutations in IDH1 or
IDH2 and are thought to have a more
favorable response to therapy (Hegi
et al., 2005). Current therapy for GBM is
focal external beam irradiation with
concomitant temozolomide. This is fol-
lowed by 6 months of temozolomide
therapy, which is thought to result in a
marginal 2.5-month improvement in
survival (Stupp et al., 2005). Unfortu-
nately, GBM remains almost universally
fatal. A recent sequencing based analysis
of paired gliomas from diagnosis andrelapse has revealed significant changes
in both driver genes and pathway alter-
ations at relapse, suggesting that tar-
geted therapies based on the tumor
genome at diagnosis are doomed to fail-
ure (Figure 1A) (Johnson et al., 2014).
Two studies reported in this issue of Can-
cer Cell by Mazor et al. (2015) and Kim
et al. (2015a) aim to answer two major
challenges in neuro-oncology, the mech-
anism driving malignant progression of
low grade gliomas, and the mechanism
of treatment resistance in GBM.
The study by Mazor et al. (2015) uses
a combined genetic and epigenetic
analysis to elucidate the driver events
and evolutionary pathways driving ma-
lignant progression of IDH mutant low
grade gliomas. Across 19 matched tumor
samples from diagnosis and progres-
sion, both genetic events and epigeneticevents were different in the recurrent
tumor as compared to the matched
untreated primary tumor. The hyperme-
thylated, ‘‘CIMP +ve’’ tumors frequently
demonstrated loss of CpG methylation
at a subset of genes in the recurrent tu-
mors, suggesting that ‘‘demethylated’’
genes might be transcriptionally activated
and acting as oncogenes. Most interest-
ingly, CpG moieties that lose methylation
during malignant progression converge
on biological pathways that have been
previously identified asGBMdrivers using
genetic approaches: components of the
G1/S cell cycle checkpoint and the RB
pathway.
The authors proceed to construct phy-
loepigenetic and phylogenetic trees from
GBM patients at presentation and recur-
rence and found that both DNA methyl-
ation (epigenetic) and mutational eventsptember 14, 2015 ª2015 Elsevier Inc. 275
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Figure 1. The Family Tree of Glioblastoma
(A) Many genetic events in the therapy naive primary tumor (as represented by the thick branches) are no
longer present in the dominant clone at the time of recurrence post therapy, as represented by the with-
ered branches lower on the trunk. New driver events, higher on the trunk, have been clonally selected at
recurrence and represent novel targets for therapy.
(B) When comparing the genetic events at recurrence (light green) and the epigenetic events at recurrence
(blue), the phylogenetic trees are highly similar.
(C) In the case of distal recurrences of primary GBM, rather than linear evolution as illustrated in (A),
branched evolution is observed in which the genetic dissimilarity of the dominant clone at recurrence is
even greater.
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pathways. Perhaps even more inter-
esting, when Mazor et al. (2015) derived
the phylogenetic and phyloepigenetic
trees for therapy naive GBM and their
matched recurrences, they found that
the trees were nearly identical and the
length of the genetic and epigenetic
branches were highly similar (Figure 1B).
This highly supports a model in which
both genetic and epigenetic events are
clonally selected during the progression
of GBM and both act as drivers. Defining
the epigenetic events driving GBM pro-
gression could allow for the design of
novel therapies, and the ‘‘driver’’ role for
epigenetic events suggests that epige-
netic modulating drugs themselves might
be effective therapies.
The study by Kim et al. (2015a) aims to
identify the clinical relevance of two previ-
ously identified observations in recurrent
GBM: 1) GBM can exhibit both linear and
branched patterns of genomic evolution
and 2) GBMs treated with temozolomide
can harbor a hypermutated phenotype at
progression (Johnson et al., 2014; Kim
et al., 2015b). Whole exome sequencing
of 38 pairs of matched therapy naive/
recurrent GBM revealed two predominant
patterns at recurrence: linear evolution,
where the recurrence is somewhat
different from the therapy naive tumor,
and branched evolution, where the recur-276 Cancer Cell 28, September 14, 2015 ª20rences are markedly different and share
as little as 11% of genetic events with
the matched therapy naive tumor
(Figure 1C) (divergent evolution second-
ary to clonal selection). An assessment
of clinical and molecular variables be-
tween patient recurrences with linear
versus branched evolution found that the
only significant difference between the
two groups was local versus distal recur-
rence, with the tumors showing branched
evolution recurring distal from the primary
site. A sobering conclusion hinted at by
the current data is that if effective therapy
is found for the local site, oncologists will
have to worry about a ‘‘whack-a-mole’’
response with the occurrence of distal re-
currences that are genomically distinct
and therefore resistant to the therapy
used to treat the local tumor.
The second important finding from the
study by Kim et al. (2015a) pertains to
the use of temozolomide. Currently, in
addition to surgery and radiation, adjuvant
temozolomide is the standard of care
for all patients with GBM. Previously it
has been shown that temozolomide can
induce a hypermutational state when
used to treat IDH mutant gliomas, and it
has been suggested that this large muta-
tional burden could provide a genetic
reservoir of genetic variants that drives
treatment resistance (Johnson et al.,
2014). The current study by Kim et al.15 Elsevier Inc.(2015a) shows that a hypermutational
state was not seen in their cohort of 20
IDH wild-type primary glioblastomas at
relapse. They did, however, recapitulate
the observation in temazolamide-treated
IDH1-mutated tumors of a dramatic in-
crease inmutational load,withone relapse
sample harboring >4,000mutations. Most
of the primary GBMs in the Kim et al.
(2015a) study received a much lower cu-
mulative dose of temozolamide than was
given to patients with IDHmutant gliomas
that have been documented to undergo
hypermutation, leaving it uncertain if the
lack of hypermutation in primary GBM is
due to the total dose of temozolamide
delivered or a fundamental difference be-
tween IDH mutant (secondary) and IDH
wild-type (primary) glioblastomas.
The model that epigenetic events help
drive malignant progression proposed
by Mazor et al. (2015) is a departure
from the current model, where progres-
sion was believed to be largely or even
solely driven by genetic events. Indeed,
this suggests that DNA methylation is
not purely a marker or ‘‘static tombstone’’
reflective of the cell of origin, but rather, at
least in the case of GBM, a dynamic pro-
cess contributing to tumor evolution. It is
unclear if epigenetic events are also
driving the process of distant recur-
rences, but the dramatic genetic diversity
of the distant relapses is startling. Charac-
terization of a larger cohort of distal re-
lapses may allow for the identification of
genes and pathways that are recurrently
affected in distal relapses and perhaps
allow for therapy to prevent those distal
relapses to be given upfront (so-called
anticipatory therapy) (Aparicio and Cal-
das, 2013).
The findings of both studies signifi-
cantly advance our current understanding
of the evolutionary dynamics of glioblas-
toma. The current model of clinical trials
relies on identification of targets based
on the biology of the initial tumor and con-
ducting clinical trials at the time of
relapse. The work of Mazor et al. (2015)
and Kim et al. (2015a) combined with
other recent studies evaluating primary-
recurrent cancers (Ding et al., 2012; Ele-
veld et al., 2015; Schramm et al., 2015)
suggest that this approach is doomed to
failure. Failure to study the tumor at
relapse risks missing not only that many
of the driver events identified ab initio
have been eliminated from the tumor at
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Previewsrecurrence, but also the opportunity to
identify novel targets in the dominant
clone at recurrence, some of which may
be eminently and imminently targetable
using existing therapeutics. Considering
the lethality of glioblastoma, we believe
the time has come for routine biopsy at
relapse in settings where targeted agents
will be employed, with the goal of identi-
fying targets still present at recurrence,
and eventually to target pathways en-
riched at relapse upfront as anticipatory
therapy.
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In this issue ofCancer Cell, Ramamoorthy and Smith report that cancer cells that maintain their chromosome
ends through alternative lengthening of telomeres (ALT) display persistent sister telomere cohesion. This de-
layed resolution of sister telomere cohesion depends upon the loss of ATRX and its histone-sequestering
function and is associated with increased recombination between sister telomeres.Telomeres in many human somatic cells
shorten with each round of replication,
whereas telomeres are maintained with
cell division in cancer cells. In 90% of
human tumors, the enzyme telomerase
is responsible for telomere maintenance
and cellular immortalization. However,
the remaining 10% of cancers lack telo-
merase expression and, in these cells,
the alternative lengthening of telomeres
(ALT) pathway counteracts normal short-
ening. ALT cells use a recombination-
based mechanism to increase the length
of telomeric DNA, but, for recombination
to occur, telomeres must encounter each
other in the nucleoplasm. One meansfor connecting two chromosome ends
in the space of the nucleus involves
one telomere traveling directionally
across large distances to find another,
using the machinery that normally drives
meiotic chromosome synapsis (Cho
et al., 2014). In this model, telomeres
can rapidly travel up to 5 mm to cluster
together and recombine. Alternatively,
telomeres can exploit the fact that,
after telomere replication in S-phase,
each chromosome end has a nearby
sister telomere that can serve as a tem-
plate for recombination at a distance of
only 0.5 mm. Mitotic cells typically use
sister chromatid recombination insteadof recombination between homologs.
Although ALT clearly relies on telomere-
telomere recombination, the relative
proportion of recombination between
sisters versus recombination between
homologs is unknown (Dunham et al.,
2000)
In this issue ofCancer Cell, Ramamoor-
thy and Smith (2015) observe that, in ALT
cell lines, sister telomere cohesions that
normally dissolve after S-phase persist
into mitosis, leading them to hypothesize
that this persistent cohesion allows the
telomeres to preferentially serve as a tem-
plate for recombination. Indeed, one of
the core molecular features of ALT cellsptember 14, 2015 ª2015 Elsevier Inc. 277
